• 2015: Expansion into the US market, incorporation of Icosagen Technologies Inc. in California.    
  • 2014: IcoPark is the new home of Icosagen's companies
  • 2013: launch of a new technology application: generation of hybridoma free recombinant antibodies
  • 2012: launch of a product line for neurobiology research: antibodies and ELISA kits for neurotrophic factors: CDNF, MANF, Artemin, etc.
  • 2010: ISO 17025 accreditation and launch of the Lab for Food Microbiology testing services
  • 2009: introduction of the new corporate name and new corporate identity - Icosagen became the new corporate name replacing Quattromed
  • 2008: 
  • launch of QMCF Technology (acronym: QuattroMed Cell Factory), first agreements to license QMCF Technology out for R&D activities to pharma companies: Bayer HealthCare, Sanofi Pasteur and Novartis
  • FITkit technology becomes an international standard
  • the business activities in the field of medical diagnostic along with the Quattromed trade mark, were sold to a VC company

  • 2007: management system complies with the requirements of the ISO 9001:2000 standard

  • 2006: submission of a PCT patent application PCT/EP2006/001275 "Vectors, cell lines and their use in obtaining extended episomal maintenance replication of hybrid plasmids and expression of gene products" 
  • 2005: 
  • establishment of two subsidiaries: Quattromed Laboratories, for medical diagnostics activities, and Quattromed Cell Factory (later Icosagen Cell Factory), for the development of QMCF Technology
  • technology platform acquisition from the University of Tartu for the development of QMCF Technology
  • acquisition of latex allergen testing business field (FITkit®) from a Finnish company FIT Biotech

  • 2001: establishment of functional proteomic lab and submission of patent application "Peptide tag for monitoring and purification of proteins"

  • 1999: molecular diagnostics company Quattromed AS was established